2929223-36-7
Chemical Structure
WX-02-43
- CAS No.: 2929223-36-7
- Formula:C26H25N3O5
- Molecular Weight:459.49
InChIKey: YCIHYSVUQSOVJT-NLFFAJNJSA-N
SMILES: C=CC(N1[C@@H](C2=CC=C(OCO3)C3=C2)C4=C(C[C@@H]1C(N5CCOCC5)=O)C6=CC=CC=C6N4)=O
Biological Activity: WX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23 (HY-168534). WX-02-43 cannot effectively covalently modify the C258 site in the DNA-binding domain of FOXA1, and its inhibitory activity against SF3B1 is also weaker than that of WX-02-23. WX-02-43 serves as a negative control probe that fails to remodel the chromatin binding pattern and transcriptional activity of FOXA1. WX-02-43 can be used in studies on cancers such as prostate cancer to verify the specific effects of WX-02-23 on FOXA1 and SF3B1 targets[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WX-02-43 | 99.89% | WX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23 (HY-168534). WX-02-43 cannot effectively covalently modify the C258 site in the DNA-binding domain of FOXA1, and its inhibitory activity against SF3B1 is also weaker than that of WX-02-23. WX-02-43 serves as a negative control probe that fails to remodel the chromatin binding pattern and transcriptional activity of FOXA1. WX-02-43 can be used in studies on cancers such as prostate cancer to verify the specific effects of WX-02-23 on FOXA1 and SF3B1 targets. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Won SJ, et al. Redirecting the pioneering function of FOXA1 with covalent small molecules. Mol Cell. 2024;84(21):4125-4141.e10. [Content Brief]
- [2]. Ng B W L, et al. Discovery of chemical probes that perturb protein complexes using size exclusion chromatography and chemical proteomics[J]. Molecular Cell, 2023, 83(10): 1544-1546.
- [3]. Lazear MR, et al. Proteomic discovery of chemical probes that perturb protein complexes in human cells. Mol Cell. 2023;83(10):1725-1742.e12. [Content Brief]
